12/28/2024
The Spanish Government, through the Centre for the Development of Industrial Technology (CDTI), has recently approved funding for four business-led R&D&I projects in Andalusia, with a total investment of €1.86 million. Among the companies benefiting from this initiative is Rekom Biotech, which will receive €315,579 for a cutting-edge project in chemiluminescence immunoassays.
Rekom Biotech’s Project: Innovating Blood Screening
Rekom Biotech’s project aims to develop advanced chemiluminescence immunoassays designed for high-throughput testing in blood banks. This innovative approach will significantly enhance the precision and efficiency of disease detection in blood donations, improving both public health and the reliability of blood screening processes.
(...)
View more
11/28/2024
We are thrilled to share that Rekom Biotech has been recognized as one of the 50 Best Biotech Blogs and Websites by Feedspot!
This achievement is a testament to our commitment to bringing innovative biotechnology insights, news, and research to our audience. We are proud to be part of this prestigious list and continue our journey to contribute to the advancement of biotech through valuable content and updates.
(...)
View more
10/21/2024
At Rekom Biotech, we have always believed in growth through innovation, and now, we are thrilled to announce a major milestone in our journey. Founded in 2010 and starting the activity in 2011, we have been steadily growing, and it is time to take the next step. In the not too distant future, we will be moving into our very own building, with a Level 2 Biosecurity laboratory. We have already completed the project design and are currently in the process of obtaining all the necessary licenses.
This new facility will open exciting doors for us. It will allow us to expand our research and production capabilities by working with new expression systems, such as insect cells and mammalian cells. Therefore, this move also positions us to introduce new product lines, including the development and production of monoclonal antibodies. Additionally, we will be able to expand into new markets, such as autoimmune diseases and cancer, all of which are key focus areas for our future growth.
(...)
View more
7/12/2024
We are pleased to announce that on July 12th, 2024, Rekom Biotech signed a new distribution agreement with Yarewell, a prominent company in the diagnostics sector in China. This agreement will allow us to expand our presence in the Chinese market, ensuring that our innovative products reach more healthcare professionals and diagnostic laboratories.
(...)
View more
8/2/2022
Rekom Biotech is delighted to announce that we have just started a new distribution partnership with Afirmus Biosource. From now on, our customers from Singapore and Indonesia will be able to purchase our IVD raw materials with the assistance of our new partner.
(...)
View more
